Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
Technology regarding new methods to efficiently and cost-effectively produce recombinant proteins from the milk of genetically-modified farm animals, applying methodologies of genetic engineering and transgenesis to pharmaceutical manufacturing. More
Researchers at the University of Edinburgh have identified two protein domains (MBD and CxxC) proven to isolate methylated and non-methylated CpG islands (CGIs), respectively. More
A new technology to address several current stumbling blocks in animal cloning. This technology dramatically enhances the probability of producing normal offspring that are truly genetically identical. More
Sensitive and quantitative assay for the screening of trinucleotide repeat (TNR) mutations. More
This cell line may be used for elucidation of the mechanisms of CF, testing candidate complementary genes for correction of the observed CF abnormalities, and for developing and testing therapeutic CF drugs. More
Novel gene scanning methodology More
The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effec More
Novel method to quantify polymorphisms in electropherograms, a new approach to the identification of ambiguous DNA sequence reads and its automation More
Your selection
Browse By
- Industry sector
- Antibodies
- Antigens
- Biomarkers
- Cell lines
- Mouse models
- Reagents
- Vectors
- Therapeutic target
- Birth defects
- Blood clotting disorders
- Fabry's disease
- Gaucher's disease
- Genetic disorder (other)
- Hunter's syndrome
- Huntington's disease
- Kawasaki disease
- Klinefelter's syndrome
- Phenylketonuria
- Severe combined immunodeficiency
- Turner's syndrome
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us